Arbutus Biopharma Corporation

NASDAQ:ABUS

Biotechnology

Healthcare
$4.11 +1.13%

+$0.05 today

Market cap
$630.03M
Beta
0.63
P/E (TTM)
5.4
EPS (TTM)
$0.83
52W Low $3.04High $5.10

Volume 2.90M

Average 1.76M

ABUS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Arbutus Biopharma CorporationNASDAQ: ABUS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $4.12M fell 54.0% year over year, ahead of the -57.1% change in trailing-twelve-month research & development. Sequentially, it fell 17.7% from the prior quarter. Over 3 fiscal years it compounded at -33.1% a year.

Context

  • Research & development amounted to 179.2% of revenue in FY2025, down 696.4 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -54.0% holds above the trailing-twelve-month pace of -57.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.12M-17.7% QoQ
Last fiscal yearDec 2025
$25.24M-53.3% YoY
LTMMar 2026
$20.4M-57.1% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-54.0%——
1 year-53.3%——
3-year CAGR-33.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
25.24M USD
Year-over-year change
-53.3%
4-year CAGR
-21.2%

Research & Development vs competitors

How ABUS compares with its peers on the latest reported figures

  • ABUS's LTM Mar 2026 research & development of $20.4M is the 8th highest of the 9 companies compared; the peer median is $125.45M.
  • Its year-over-year change of -57.1% is the lowest of 8, against a peer median of +10.1%.
  • Research & development amounts to 10.7% of revenue for ABUS, versus a peer median of 147.9%.
ABUS Competitors Peer median
Research & Development for ABUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.51B +30.1%+14.5%31.4%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$739.14M +21.7%+29.3%164.0%
VIRVir Biotechnology, Inc.LTM Mar 2026$446.24M -15.0%-3.0%681.3%
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M +37.4%+18.6%—
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$64.86M +10.1%-2.5%91.2%
SLNSilence Therapeutics plcLTM Mar 2026$61.84M —+24.0%6710.8%
ABUSArbutus Biopharma CorporationLTM Mar 2026$20.4M -57.1%-33.1%10.7%
BNTCBenitec Biopharma Inc.LTM Mar 2026$19.2M +1.2%+17.6%—
Peer median (excluding ABUS) $125.45M+10.1%+16.0%147.9%

Competitors are the stored peer set for ABUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.99M39.02M18.14M6.17M14.08M
Cost of Revenue0000363K
Gross Profit10.99M39.02M18.14M6.17M13.72M
Gross Margin100.0%100.0%100.0%100.0%97.4%
Research & Development65.5M84.41M73.7M54.04M25.24M
Selling, General & Admin17.14M17.83M22.48M22.11M15.89M
Operating Expenses84.51M104.48M96.24M82.49M40.77M
Depreciation & Amortization1.75M1.43M1.4M1.38M363K
EBITDA(71.64M)(61.86M)(70.99M)(68.4M)(33.04M)
EBITDA Margin-652.0%-158.5%-391.3%-1108.5%-234.6%
Operating Income(73.52M)(65.46M)(78.1M)(76.32M)(27.05M)
Operating Margin-669.1%-167.8%-430.5%-1236.7%-192.1%
Interest Income127K2.19M5.69M6.59M4.07M
Interest Expense2.86M1.73M459K137K97K
Other Income / Expenses(2.73M)444K5.25M6.4M(6.45M)
Income Before Tax(76.25M)(65.01M)(72.85M)(69.92M)(33.5M)
Pre-Tax Margin-693.9%-166.6%-401.6%-1133.0%-237.9%
Income Tax Expense04.44M000
Net Income(76.25M)(69.46M)(72.85M)(69.92M)(33.5M)
Net Margin-693.9%-178.0%-401.6%-1133.0%-237.9%
EPS (Basic)(0.73)(0.46)(0.44)(0.38)(0.17)
EPS (Diluted)(0.73)(0.46)(0.44)(0.38)(0.17)
Weighted Avg Shares106.24M150.94M165.96M185.61M191.6M
Weighted Avg Shares (Diluted)106.24M150.94M165.96M185.61M191.6M

Arbutus Biopharma Corporation

NASDAQ:ABUS

Intrinsic Alpha fair value

Locked

Current Price

$4.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.